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Key Points:  
 Adherence to oral agents appears to be a significant clinical problem, with non-adherence rates ranging 
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ABSTRACT 
Background. The use of oral chemotherapy agents to treat cancer has increased. Patients are responsible for 
adhering to complex dosing regimens, while monitoring and managing symptoms from side effects of the 
chemotherapy at home.  
 
Objective. This study examined an intervention to manage symptoms and promote adherence to oral 
chemotherapy agents. 
 
Intervention and Methods. A 3 group exploratory pilot study determined how an Automated Voice Response 
(AVR) system alone (N=40), or the AVR with strategies to manage symptoms and adherence (N=40), or the 
AVR with strategies to manage adherence (N=39) reduced symptom severity and improved adherence. 
Participants received a Symptom Management Toolkit, completed a baseline interview, and were randomized 
to receive 8 weekly AVR calls. The AVR directed patients to the toolkit for high symptoms and nurse calls 
occurred for management of severe symptoms or non-adherence. An exit interview occurred at 10 weeks.  
 
Results. Mean age was 59.6, with 70% female and 76% Caucasian. Overall, 42% of patients were non-
adherent, with missed doses increasing with regimen complexity. Symptom severity declined over time in all 
groups. No difference was found in adherence rates among intervention groups. Higher adherence rates were 
related with lower levels of symptom severity across groups.  
 
Conclusions. Adherence is a significant clinical problem, which can affect efficacy of the cancer treatment. 
The AVR intervention alone was just as effective as the AVR plus the nurse intervention at promoting 
adherence and managing symptoms from side effects.  
 
Implications for Practice. Nurses need to focus on patient education by assuring patient understanding of 
oral agent regimen, and the need to adhere to the oral agent for efficacious cancer treatment. Nurses can 
promote the use of medication reminders and self- management of symptoms from side effects, to support 
adherence to the oral agent. 
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Introduction 
A new generation of targeted oral chemotherapy agents is transforming cancer treatment. At least 25% 
of all cancer treatments in development are oral agents, and this mode of administration is likely to increase 
dramatically in coming years. 1 This new treatment paradigm shifts delivery of chemotherapy from a safe, 
controlled process monitored on a regular basis by oncologists and oncology nurses in clinics, into patients’ 
homes. 2 Patients and their families are responsible for adherence to complex dosing regimens, monitoring 
symptoms, detection and management of side effects and toxicities, and coordination of drug delivery, and 
changes in dosing if altered or stopped. 3-5 The more adherent patients are to the oral chemotherapy agents, 
the more likely they are to experience symptoms. Patients prescribed oral chemotherapy agents have 
indicated titrating doses as they were unable to tolerate symptoms occurring as a side effect of the cancer 
treatment. 6 Thus, prompt and aggressive management of symptoms becomes vital to adherence. 
Furthermore, pharmacy literature suggests a narrow therapeutic index for cancer therapy, 2 increasing the 
importance of oral agent adherence, as non-adherence may affect time to disease progression, and mortality. 
To address this problem, this exploratory study tested an intervention to promote adherence and management 
of symptoms in patients receiving oral chemotherapy agents. This study was guided by the following 
framework.  
Framework for this Study 
The “Intervention for Symptom Management Model” developed by Given and Given,  7 8 and used in 
several previous studies, guided this study. The model is based on a behavioral intervention framework for 
symptom management, grounded in cognitive modifications that lead to behavior change. Earlier studies 
established the superiority and cost effectiveness of interventions for symptom management over and above 
conventional care. 9 10 Consequently, symptom severity interference cut-points have been previously identified, 
establishing thresholds necessitating symptom management. 11The model was then expanded to include 
adherence for this study (Figure 1).  
Building on past work, and guided by our framework, we conducted this exploratory study to examine 
differences in adherence and symptoms, and if the intervention for symptom strategies and/or promoting 
adherence improved adherence among intervention groups. Therefore, an educational approach to symptom 
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management coupled with medication reminders, and a cognitive behavioral intervention using directed 
strategies to manage symptoms and/or adherence was developed. An automated telephone response system 
merged computer software to a prerecorded voice for phone calls. Patients were called at a desired time, and 
their responses were recorded using the touch-tone pad of a telephone. Based on patient responses to 
symptom severity and adherence levels, interventions were tailored to patient needs. Overall, patient 
evaluations indicate that automated systems have high usability and acceptability, 12 and are more accurate 
than in-person interviews in obtaining sensitive information. 13 14  
Research questions included the following. 1) Was there a difference in oral agent adherence among 
intervention groups? 2) Was there a difference in symptom severity among intervention groups? 3) Was there 
a relationship between symptom severity and adherence across the groups? Regardless, of whether 
symptoms are related to the cancer disease or to side effects of the oral agent, we believed patients would be 
more likely to follow their chemotherapy regimen if symptoms were manageable. Our assumption was that 
lower symptom severity would lead to improved adherence, thus, interventions that supported management of 
symptoms and promote adherence to the oral agent would have higher rates of adherence. To answer these 
questions we examined and compared symptom severity and adherence to oral agents among three groups 
over the 8 weeks of the intervention.   
 Group 1 used a Symptom Management Toolkit® (SMT) and an Automated Voice Response (AVR) 
phone system alone.  
 Group 2 used the AVR system and SMT complemented by nurse strategies to manage unresolved 
symptoms and improve adherence.  
 Group 3 used the AVR system and SMT complemented by nurse strategies to improve adherence 
alone.   
We choose to use these groups so we could explore the three components the intervention, the AVR, 
the nurse intervention for adherence, and the nurse intervention strategies to manage symptoms, to inform 
planning of interventions for future studies. We examined each group to determine if the intervention reduced 
symptom severity and improved adherence to the oral chemotherapy agent. Our study was powered to detect 
a medium effect size of 0.50 for pair-wise differences between groups on symptom severity and adherence.  
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Background and Literature Review 
Medication Adherence 
      In a quantitative review of 50 years of research, DiMatteo 15 found that medication adherence is approximately 24.5%. 
Studies focused on chemotherapy are reported in recent Seminars in Oncology Nursing articles by this research team, 
showed adherence ranging between 20% and 100%. 16-18 Several key points can be gleaned from these oral agent 
studies.  Factors influencing adherence included complexity of the dosing regimen, the disease, side effects from both the 
disease and the treatment, long-term use of the drug, and depression. However, there was no consistent definition of 
adherence used across the studies. For example, one study used 80% of the medication taken as being adherent, while 
another used 100% of the medication taken as being adherent. This makes it difficult to compare adherence rates across 
studies. The International Society for Pharmaco-economics and Outcome Research defines adherence as “the degree or 
extent of conformity to the recommendations about day-to-day treatment by the provider with respect to the timing, 
dosage, and frequency” for “the duration of time from the initiation of the medication to discontinuation of therapy;” thus, 
capturing the complexity of dosing regimens for oral agents. 19  
Medication Adherence Relationship with Side Effects and Symptoms 
Overall, studies of chronic diseases indicate that patients decrease adherence to medications as 
symptoms and side effects occur. 20 Studies have shown this to occur with  cancer patients, 21 22 however, 
much of this work has been conducted on hormonal anti-cancer agents. 23 24 This study is among the first to 
consider adherence to oral chemotherapeutic agents and examine a relationship between adherence and 
symptom severity.  
Evidence Based Interventions to Improve Symptoms 
There are numerous evidence based interventions reported elsewhere in the literature. AVR systems 
began to be tested around the turn of the century, and their use in delivering interventions has been 
summarized in the literature. 25 26 Among studies using AVRs for interventions, most patients were satisfied 
with this mode of delivery and reported improvement in their condition. 25 26 Anastasia and Blevins 26 introduced 
a phone triage system for symptom management, which detailed how assessments for common symptoms 
may be completed through a phone system.  Findings of a cognitive behavioral intervention using an AVR in 
two previous studies by this team reduced cancer patient symptom severity. 8 10 27 In this study we build upon 
our previous work, extending the intervention to adherence. 
Evidence Based Interventions to Improve Medication Adherence 
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 A Cochrane Review found interventions that are multifaceted, including combinations of convenience, 
information reminders, self-monitoring, reinforcement, counseling, psychological therapy, telephone follow-up, 
and supportive care improved adherence. 28 Interventions found to improve adherence in cancer patients 
include symptom management logs and pro-active nursing follow-up. 29 30 No studies were found using the 
AVR to simultaneously address symptom severity and adherence.  
Multidimensional interactive interventions using the AVR system to manage symptoms experienced by 
cancer patients have demonstrated effectiveness. 7 9 Additionally, psychoeducational strategies have 
demonstrated effectiveness at improving medication adherence in other diseases, specifically in difficult-to-
manage psychiatric disorders and in those with HIV. 28 However, few symptom management or adherence 
strategies have been tested among patients taking oral agents, and fewer still using AVR for adherence, which 
led to the development of this study.  
Methods 
Sample and Procedures 
The Institutional Review Boards of the university and each collaborating site approved this research. 
Subcontracts were established, and nurses from the sites were hired and trained to implement the recruitment 
protocol. Accrual of patients occurred between September 2008 and January 2010 at a National Cancer 
Institute (NCI) designated Community Clinical Oncology Program, a large private oncology practice in the 
Midwest, a Comprehensive Cancer Center, and an NCI designated Comprehensive Cancer Center. Eligibility 
requirements included being 21 years of age or older, having a solid tumor cancer diagnosis, and on non-
hormonal oral agents, understood English, having a touchtone phone and no hearing deficits that interfered 
with using a telephone, having no cognitive deficits, willing to complete phone contacts, and not being 
diagnosed with an emotional or psychological disorder. Figure 2 shows the number of patients entering and 
completing each phase of the study. 
Patients were identified by the nurse recruiters, and those who consented received a copy of the SMT. 
The SMT is a bound notebook of supplemental information that is organized into a Frequently Asked 
Questions format and covers what is needed to manage side effects from the cancer or cancer treatment. 11 
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The SMT has been used in several studies and is well accepted by patients. 8 31 A baseline interview was then 
conducted by trained interviewers.  
Measures 
Baseline measures included characteristics (sex, age, race), cancer site, depressive symptoms (using 
the Center for Epidemiological Studies Depression Scale [CES-D]), and oral agents complexity (daily regimen, 
or cycled regimen), whether on intravenous therapy or supportive prescription drugs, and adherence to the 
agents regimen for the past 7 days prior to the study.  
 
The Symptom Experience Inventory was used to assess symptom severity by collecting information on 
each of the 15 common symptoms from side effects of chemotherapy (fatigue, pain, insomnia, poor appetite, 
constipation, nausea/vomiting, anxiety, cough, depression, diarrhea, mouth sores, shortness of breath, 
peripheral neuropathy, difficulty remembering, and weakness). Patients were asked if, within the past 7 days, 
they had experienced each symptom (yes/no) and, if so, to rate the symptom on a scale of 0 (did not occur), 1 
(barely noticeable) to 10 (worst imaginable).The inventory was developed in past studies by Given et al, 9 11 32 
and has internal consistence reliability of .79.  
Adherence was measured by patient self-report over the past 7 day time period, which was then 
compared to prescribed oncologist orders, and pharmacy fill records. We also conducted medical record 
reviews to evaluate prescription changes for dosage modifications. We evaluated adherence for each 7 day 
time period during the 8 weeks of the study using the following definitions.  
For this study, adherence was defined as taking from 80% to 100% of the prescribed oral agent dosage 
during the immediate past 7 day time period. We defined over-adherence as taking the oral agent during any 
prescribed rest period. We defined under-adherence as missing more than 20% of the pills during any 7 day 
time period.  For analysis of symptom severity and adherence (research question 3), repeated weekly 
measures of the binary variable of adherence (1=adherence, 0=non-adherence [either over- or under-
adherence]) were used. For research question 1, a cumulative determination of adherence was made over 8 
weeks: those who were adherent during weeks 2 to 8 were classified as adherent over the 8 week period; 
those who reported over- or under-adherence were classified as non-adherent over the 8 week period.    
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Procedures 
After completion of the baseline interview, patients were randomized into the groups. Patients in Group 
1 received calls from the AVR system, symptoms were assessed, and those reporting severity at a 4 or higher 
on a 0 to 10 scale for any symptom were referred to the SMT for self-management of symptoms. Adherence to 
oral agents was identified via patient report (no nurse was involved). In Group 2, in addition to the AVR calls, 
for those patients with one or more symptoms rated at a 4 or greater or non-adherence defined as less than 
80% or 100%  probably needs to be the same as 3??? for the past two consecutive weeks.  for 2 weeks 
received a brief telephone call from the nurse to deliver strategies to assist patients to manage symptoms 
and/or improve their adherence.  
Patients were called weekly until symptom severity fell below 4 or until adherent. In Group 3, in addition 
to the AVR calls, patients received brief calls from a nurse when the adherence rate was less than 100% to 
improve their adherence. Patients were called weekly until adherent. When the specially trained nurse was 
notified to contact Group 2 patients regarding severe symptoms, she used, in addition to the SMT, a previously 
designed and randomized control trial proven symptom management protocol to guide delivery of intervention 
strategies. This included enhanced tailored behaviors for each specific symptom, fostering self-care behaviors, 
problem solving for adherence to the self-care symptom behavior, providing support, coaching and counseling, 
and decision making. 8 33   
For adherence rates of less than 100%, the AVR notified the nurse to contact the patient (Group 2 and 
3). The nurse made a brief telephone call, verified the non-adherence, and delivered strategies to assist 
patients to improve their adherence. These strategies included use of a calendar, a pillbox, or a reminder 
system such as a watch or phone alarm, or obtaining the help of a friend or family member to remember when 
to take the oral agent. A 10-week exit telephone interview was administered to all patients; symptoms, 
depression, and adherence were assessed. Medical records were audited for dose changes and adverse toxic 
events. Specialty pharmacies were contacted to obtain the scripts filled to further measure adherence from 
multiple perspectives by comparing the dosage prescribed to that obtained from the pharmacy. In sum, all trial 
arms received weekly symptom assessment with referral to the SMG. The second arm, in addition , received 
calls from  a nurse  when one or more symptoms were scored at a 4 or higher  and /or adherence dropped 
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below 100% for two consecutive weeks  The third arm added nurse calls when adherence dropped below 100 
for  2 consecutive weeks  I think you need to summarize this  so it  is clear  how comparisons are  analyzed.  
Data Analyses  
The intent-to-treat analysis, based on the initial assignment to a group was adopted. 34 35 This statistical 
approach allows all patients to be analyzed as randomized, regardless of their adherence with the intervention 
protocol. This analysis strategy yields conservative estimates of differences among groups.  
Categorical variables, such as sex, age, race, cancer site, and oral agent complexity, administration of 
intravenous therapy or supportive prescription drugs, and adherence to the regimens for the past 7 days prior 
to baseline were compared by group using chi-square tests at baseline. Means of continuous variables such as 
baseline symptom severity, and baseline summed CES-D scores were compared among groups using 
analysis of variance (ANOVA). The characteristics of those who dropped out were compared by study groups 
using chi-square tests and ANOVA as appropriate. Research question 1 related to difference among groups on 
adherence and was addressed by comparing overall adherence over 8 weeks in the 3 groups. Low counts of 
over- and under-adherence did not allow for reliable statistical inference. Thus, the summary distributions of 
adherence are reported overall and by group. Research question 2 and 3 related symptom severity to group 
and adherence to address our research questions. 
We used Generalized Estimating Equations (GEE) with gamma distribution and autoregressive 
correlation matrix of the first order [AR(1)] to relate symptom severity at AVR call 1 to 8 to  the time-varying 
covariate of adherence while adjusting for baseline symptom severity and patient characteristics. The gamma 
distribution accounts for the highly right skewed distribution of symptom severity; while the first order 
autoregressive correlation matrix accounts for the correlation of multiple measurements over time  within the 
same patient. The explanatory variables included study group and time. This exploratory study was not 
powered to detect interactions, thus only main effects were included in the statistical models. 
 
Findings 
In total, 149 patients met the inclusion criteria and consented, and 119 completed the baseline 
interviews (Figure 2). After randomization there were 40 patients in Group 1 and 3, and 39 patients in Group 2. 
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In total, 91 patients (31, 29, and 31 respectively) completed the study. 
Attrition Analysis 
A total of 28 out of 119 dropped out of the study. Six patients dropped out of the study in each group 
between AVR calls 1 and 4; fewer patients dropped out between AVR calls 5 to 8 (1, 3, and 5 respectively). 
There were no differences among drop-outs from the 3 groups with respect to age (p=0.08), or race (p=0.06), 
but differences in cancer site was significant (p=0.03). To inform generalizabilty of findings, we compared 
those who dropped out to those who stayed and found those who were older (70+), other than white, and lung 
cancer patients were more likely to withdraw from the study. Baseline CES-D, total symptom severity and 
individual symptom severity at baseline were compared for those who stayed and those lost. No significant 
differences were found, except regarding severity of shortness of breath (p=0.04), as those with moderate or 
severe shortness of breath were more likely to withdraw from the study.  
Sample Characteristics 
Table 1 summarizes patient and clinical characteristics. Overall, the average patient age was 59.6. 
There were more females than males (69%, N=82 to 31%, N=37), and the racial or ethnicity distribution 
reflected the distribution in the source population of adult cancer patients taking oral agents treated at 
participating oncology settings.  
Of those, 33% (N=39) had breast, 25% (N=30) had lung, and 9% (N=11) had colon cancer, while 33% 
(N=39) were all other types of cancer. A total of 46% (N=55) were on simple medication regimens, taking the 
medication at the same time every day; while 54% (N=64) were on more complex regimens, varied cycles of 
on-off, rest periods, or changing medication schedules. Of those, 25% (N=29) were simultaneously on 
intravenous chemotherapy, and 27% (N=31) were taking supportive drugs.  
Oral agents varied and included: capecitabine (35%, N=42), erlotinib (24%, N=24), lapatinib (9%, 
N=11), imatinib (8%,N=9), temozolomide (6%, N=7), sunitinib (5%, N=6), sorafenib (2.5%, N=3), methotrexate 
(1.7%, N=2), cyclophosphamide (0.8%, N=1), and all others (8%, N=9). At the start of the study, 14% (N=17) of 
the patients reported being non-adherent to their oral agents. Despite randomization, baseline symptom 
severity and CES-D scores were significantly different among groups, with patients in Group 3 (AVR plus the 
nurse for adherence management) having higher symptom severity and CES-D scores. The values of 
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symptom severity and CES-D at baseline were included in all models, as covariates to adjust for lack of 
equivalence of groups at baseline. 
Research Question 1: Study Group Comparisons on Adherence Rates   
The first research question examined the difference in the adherence rates among study groups. 
Although overall, we found a 42% (N=50) non-adherence rate, there were no significant differences found 
among the study groups. Additional analyses were performed to determine whether adherence rates differed 
during AVR calls 1 to 3 and weeks 4 to 8. We found differences among groups during AVR calls 1 to 3 
(p=0.04), with the AVR plus nurse for symptoms and adherence in Group 2 having the highest rate of non-
adherence (40%, N=16), compared to the AVR alone Group 1 (18%, N=7) or the AVR plus nurse for 
adherence only Group 3 (18%, N=7). No differences were found for weeks 4 to 8 (p=0.67). Since patients 
skipped some AVR calls, the number of contacts varied, and might have influenced these findings.  
To examine this further, we calculated mean adherence rates for those patients who completed all 8 
AVR calls (N=67). We found adherence rates increased by 9% (p=0.11) in the AVR plus nurse for symptoms 
and adherence strategies. We found adherence rates increased by 3% (p=0.54) in the AVR plus nurse for 
adherence only. While we found adherence rates declined by 4% (p=0.36) in the AVR plus SMT only arm. 
Although no statistically significant differences were found (in part, due to sample size), it can potentially be 
viewed as a clinically important difference in adherence rates.  
To complement the analysis of adherence based on self report, we examined adherence based on the 
medical record audit (N=100 of 119) and prescription fill rates. We had 67 patients who adhered to their oral 
agents and 33 patients who were non-adherent. Of those who were non-adherent, we found two distinct 
problems: 1) under-adherence, taking less of the oral agent than prescribed (13%, N=13 of 100), and 2) over-
adherence, taking more of the oral agent than prescribe (20%, N=20 of 100). The number of cases with non-
adherence ranged from 7 patients with one instance of over adherence, to 1 patient reporting 9 instances of 
over-adherence. Missed medication doses increased with oral agent regimen complexity, thus, we found that 
adherence rates by complexity of regimen were very different. For those with a continuous regimen (defined in 
our study as 28 days on), we found an 88% (N=51 of 57) adherence rate, thus, 12% were non-adherent. For 
those regimens with the 14 days on and 7 days off regimen we found a 35% (N= 9 of 25) adherence rate, thus, 
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65% were non-adherent. For those on a 7 days on and 7 days off regimen we found a 33% (N=3 of 9) 
adherence rate; thus 67% were non-adherent. For all other types of complex regimens we found a 50% (N=4 
of 8) adherence rate. Therefore, we found rising non-adherence rates, of 12% to 35% to 67%, as the 
complexity of the regimen increased.  
Research Question 2: Study Group Comparisons on Symptom Severity 
The second research question addressed the difference in the symptom severity (summed symptom 
severity index of 15 symptoms) among study groups, as shown in Table 2. Baseline mean symptom severity 
for all patients was 20.4 (Standard Deviation [SD] 15.4), however, a significant difference was found among 
groups, with the lowest at 16.9 (SD 11.8) and the highest at 26.0 (SD 16.7) (p=0.02). To control for this 
difference, symptom severity at baseline was used as a covariate in statistical models described below. Exit 
mean symptom severity for all patients was 14.7 (SD 14.0), and again, a significant difference was found 
among groups, with the lowest at 11.0 (SD 10.4) and the highest at 20.1 (SD 17.0) (p=0.04).    
In order to determine whether symptom severity within each group increased, decreased or remained 
the same during the 10 weeks of the study, pair-wise comparisons of symptom severity at baseline and 10 
weeks within each group were performed.. Group 1 (mean score decreased 4.74, p=0.03) and Group 2 (mean 
score decreased 6.76, p=0.04) had a significant decrease in symptom severity from baseline to end of the 
study. However, Group 3 did not have a significant decrease in symptom severity (mean score decreased 
2.16, p=0.39) from baseline to end of the study.  
Research Question 3: Study Group Comparisons on Adherence and Symptom Severity 
The third research question examined the relationship between symptom severity and adherence 
across the groups. First we examined if the number and percentage of patients who reported adherence less 
than 100% and the number of symptoms above threshold (severity 4 or higher) differed by study group and the 
number of AVR contacts (1 to 3 versus 4 to 8). No significant difference was found (Table 2). The comparison 
of adherence rates during AVR calls 1 to 3 compared to calls 4 to 8 revealed that more patients in Group 2 
(AVR plus the nurse for both symptoms and adherence) reported non-adherence during the beginning of AVR 
calls (1 to 3) (p=0.04), however, as the AVR contacts continued (calls 4 to 8), these differences disappeared 
(p=0.67). Generalized estimating equations (GEE) model addressed the relationship between symptom 
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severity and adherence over time. We found mean symptom severity of patients who over adhered by the end 
of the study was 19.0 compared to 13.0 among those who adhered, a significant difference. 
Table 3  lists the estimated parameters and associated p-values for the explanatory variables in the 
model. The least square means derived from the model are listed in Table 4.  Adjusted for other covariates, 
males had a higher symptom severity at 18.7 (Standard Error [SE] .09) compared to females 13.8 (SE .09) with 
a p-value of 0.01. Study Group 1 had overall adjusted mean symptom severity of 15.4 (SE .12), 15.9 (SE .09) 
in Group 2, and Group 3 was 16.9 (SE .08). However, no significant difference in symptom severity over time 
was found among groups.   
The GEE model indicated that from the AVR calls 1 to 4, the symptom severity (adjusted means as 
22.5, 18.9, 16.7, and 16.1) sequentially decreased. The symptom severity at call 8, AVR call 1 (22.5), call 2  
what does this mean  8 vs avr call 1what is avr  call 8 and(18.9), call 3 (16.7), and call 4 (16.1) was significantly 
higher (p<0.01, 0.01, 0.05, 0.05) when compared to AVR call 8 (14.1). However, no significant difference could 
be found between AVR call 5 to AVR call 8. Adjusted for other covariates, patients who reported adherence 
had lower levels of symptom severity than those who were non-adherent, 15.17 compared to 17.0 respectively. 
However, this effect was not significant, due to the small sample size.  
Discussion 
Based on patients’ self-reports for all AVR contacts, the symptom severity declined over time, and 
adherence at each AVR call was related with lower levels of symptom severity in this exploratory study. The 
AVR alone (Group 1) was just as effective at managing symptoms and adherence as the AVR plus the nurse 
strategies (Group 2). We found that the AVR and nurse calls for symptoms and adherence (Group 2) had 
greater decrease in symptom severity score compared to the AVR and nurse for adherence only (Group 3). 
However, we only had 12 patients (10%) who received brief nurse intervention calls for symptom severity. This 
suggests that interventions may have had some effect on symptoms, and consequently adherence. However, 
given the small N for which calls were completed, this conclusion is, at best, equivocal.  
 
The non-adherence rate for the AVR and nurse intervention for symptoms and adherence (Group 2) 
was the highest at 53%; the AVR alone (Group 1) was second highest at 40%; and the AVR and nurse 
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intervention for adherence only (Group 2) was the lowest at 33%. However, differences in adherence rates 
between AVR calls 1 to 3 and AVR calls 4 to 8 were found. This suggests one of two possibilities: as patients 
were able to manage their symptoms they improved adherence to oral agents; or as patients were non-
adherent (probably under adherence [taking less of the oral agent than prescribed]) their symptoms were less 
severe. Again this finding is interesting but the association does not meet standards for significance, and thus, 
is suggestive but awaits further study for confirmation.  
Over time, the AVR only group (Group 1) had a decline in the rate of adherence by 4% (92% to 88%). 
The number of AVR contacts with the patient seemed to make a difference. As patients were exposed to a 
greater number of contacts, the detection of the non-adherence rates had a tendency to increase. This only 
occurred in the AVR only group. While in both the nurse call group that received interventions for symptoms 
and adherence and the nurse call group with interventions for adherence only, the opposite occur, as over time 
the tendency was to increase the rate of adherence.   
 
Conclusion 
As demonstrated in this study, adherence levels with oral agents are a significant clinical problem. We 
found symptom severity, depressive score, sex, and age were not associated with adherence, whereas site of 
cancer was, as the drug and drug regimen depended on types of cancer. This is consistent with the literature. 
16 The complexity of the medication regimen influences adherence, as patients with continuous regimens had 
better adherence than the patients with intermittent regimens. This finding is also consistent with the literature 
on medication adherence in general, and with oral agents, as patients who are less confused with dosing are 
more likely to adhere to their regimens.  16 In this study, in addition to the complexity of the regimen causing 
difficulty with adherence, side effects from the oral agents with subsequent symptoms seemed to create 
difficulty for patients, consequently leading to non-adherence, again consistent with other findings. 16  
Although the number of patients with each instance of non-adherence was small, both over adherence 
(taking more of the oral agent than prescribed) and under adherence (taking less of the oral agent than 
prescribed) were related to symptom severity. More instances of over adherence (taking more of the oral agent 
than prescribed) were related with higher symptom severity. Conversely, more instances of under adherence 
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(taking less of the oral agent than prescribed) lead to lower symptom severity and greater decrease in 
symptom severity.  
Implications for Research 
 This study provides several implications for future research, including process, outcome, and system 
studies. Studies examining how patients are instructed to conduct self care management of symptoms and 
adherence need to be undertaken. Consequently, interventions need to be developed, extending evidence 
based practice on symptom management and adherence into the home setting for patients prescribed oral 
agents. Over adherence needs to be examined using more refined measures that reflect the timing of dosages 
of certain types of complex oral agents, as some require specific timed dosages. Further, ifa patient forgets to 
take their medication one day and doubles up on a dose the next day, over adherence may occur. We also 
know very little in regard to the level of symptom experience by patients receiving oral agents, outside of the 
drug trials.  
Implications for Nursing Practice   
With the rise in use of oral agents, nurses need to be aware that adherence to complex medication 
regimens is a significant problem, and that focusing on symptom management can promote adherence. This 
study demonstrated that the AVR is a flexible, low cost, integrated approach to supporting self-management of 
symptoms and monitoring adherence to oral agents. Patient assessment is available in real time, is convenient 
and easy to use for patients and providers, and accessible anywhere at any time. Multiple symptoms can be 
monitored longitudinally, and self-managed and referred to a clinician for further guidance as needed.  
However, future research needs to be conducted on a broader range of patients.  
For those nurses who do not have access to an AVR to assist in patient care, they can focus on several 
items. First, nurses need to educate patients on drug regimens start and stop cycle, and rest periods. Second, 
nurses need to help patients understand common side effects, symptoms, and how to manage those 
symptoms and to adhere to oral agents. Third, nurses need to train patients in how to effectively communicate 
with clinicians regarding symptom severity and adherence prior to starting any oral agent regimen. This should 
include helping patients understand which symptom severity levels and occurrences of oral agent non-
adherence should be reported to their clinician.  Finally, nurses must help patients understand the need to 
16 
 
adhere to oral agents for efficacy in cancer treatment. In sum, this study challenges the myth that cancer 
patients adhere to their oral agents, thus, compromising the therapeutic index needed when administering oral 
agents.   
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Table 1. Patient Sex, Age, Race, Cancer Site, Oral Agents Complexity, IV Therapy, Supportive Drugs, Adherence, Symptoms, and CES-D by 
Group at Baseline Interview 
 All patients AVR only  AVR+Nurse AVR+Nurse for   
   for Symptoms Adherence Only 
         and Adherence 
 N=119 N=40 N=40      N=39 p-value 
 N (%) N (%) N (%) N (%) 
Sex 
Female 82 (68.9) 24 (60.0) 29 (72.5) 29 (74.4) .32 
Male 37 (31.1) 16 (40.0) 11 (27.5) 10 (25.6)  
 
Age 
<50 Years 29 (24.4)   9 (22.5) 10 (24.0) 10 (25.7) .09 
50 to <60 Years 22 (18.5)   2 (5.0) 12 (30.0)   8 (20.5) 
60 to <70 Years 35 (29.4) 17 (42.5)   8 (20.0) 10 (25.6) 
70+ Years 33 (27.7) 12 (30.0) 10 (25.0) 11 (28.2) 
 
Race 
Caucasian 91 (76.5) 32 (80.0) 28 (70.0) 31 (79.5) .82 
Black   8 (6.7)   3 (7.5)   4 (10.0)   1 (2.6) 
Other 20 (16.8)   5 (12.5)   8 (20.1)   7 (18.0)  
 
Cancer Site 
Breast   9 (32.8)   9 (22.5) 15 (37.5) 15 (38.5) .42 
Colon/rectal 11 ( 9.2)   5 (12.5)   1 (2.5)   5 (12.8) 
Lung 30 (25.2) 11 (27.5) 10 (25.0)   9 (23.1) 
Other 39 (32.8) 15 (37.5) 14 (35.0) 10 (25.6) 
 
Oral Agent Regimen  
Complexa 55 (46.2) 17 (42.5) 18 (45.0) 20 (51.3) .72 
Non-complexb 64 (53.8) 23 (57.5) 22 (55.0) 19 (48.7) 
 
Concurrent IV Chemotherapy 
Yes 30 (25.2)   8 (20.0)   9 (22.5) 13 (33.3) .35 
No 89 (74.8) 32 (80.0) 31 (77.5) 26 (66.6) 
 
  Mean (SD) Mean (SD) Mean (SD) 
 
Baseline CES-D  8.0 (5.0) 11.3 (7.9) 11.5 (6.5) .03 
 
a Complex oral agent is defined as patients who take the regimen(s) at varied times, days, or cycles for one or more of their types of oral agents. 
 b Non-complex oral agents complexity is defined as patients who take the same regimen every day.  
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Table 2. Symptom Severity by Study Group 
 
 All Patients  Group 1 Group 2 Group 3 Chi-square 
 in Study AVR Only AVR+Nurse AVR+Nurse p-value 
   Symptoms/ Adherence 
   Adherence Only 
 N=119* N=40 N=40 N=39    
 
N (%)  N (%) N (%)   N (%) 
 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 
Baseline Symptom 20.4 (15.4) 16.9 (11.8) 18.5 (16.1) 26.0 (16.7) .02 
 
Exit Symptom 14.3 (14.0) 11.0 (10.4) 11.6 (12.1) 20.1 (17.0) .04  
Severity 
 
Maximum Number of Symptoms Reported over Threshold a 
AVR Calls 1-3 
0-2 Symptoms 56 (49) 22 (58) 16 (42) 18 (47) .58 
3-5 Symptoms 42 (37) 12 (32) 17 (45) 13 (34)  
6-8 Symptoms 16 (14)   4 (11)   5 (13)   7 (19) 
 
AVR Calls 4-8 
0-2 Symptoms 63 (640) 20 (61.0) 23 (68.0) 20 (63.0) .91 
3-5 Symptoms 24 (24.0)   8 (24.0)   7 (21.0)   9 (28.0)  
6-8 Symptoms 12 (12.0)   5 (15.0)   4 (12.0)   3 (9.0) 
 
 
a Threshold was defined as a symptom severity of 4 or higher on a 0 to 10 point scale.  
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Table 3. Generalized Estimating Equations Model Relating Symptom Severity at Contacts 1-8 to Symptom Severity at Baseline, Study , Study 
Group, Time, and Adherence.  
 
Parameter Estimate of Standard  95%  p-value 
 Baseline   Error Confidence 
 Coefficient  Interval 
 
Intercept 1.97 0.14 1.69 2.25 <.001 
 
Baseline Interview  0.02 0.004 0.02 0.03 <.001 
Symptom Severity Score   
 
Groups 
Group 1: AVR Only -0.09 0.14 -0.36 0.18 .52 
 
Group 2: AVR + Nurse    
for Both Symptoms 
and Adherence -0.06 0.12 -0.01 0.24 .60 
 
Group 3: AVR + Nurse 
for Adherence Only 
(Referent) 0.00 0.00 0.00 0.00  Referent 
 
Adherence 
Non-adherence 0.11 0.06 0.07 0.54 .08 
Adherence (Referent) 0.00 0.00 0.00 0.00 Referent 
 
Sex 
Male 0.30 0.12 0.07 0.54 .01 
Female (Referent) 0.00 0.00 0.00 0.00 Referent 
 
Contact (AVR Call Number) 
1 0.44 0.09 0.30 0.64 <.00 
2 0.26 0.10 0.11 0.46 .01 
3 0.17 0.09 0.03 0.32 .05 
4 0.14 0.07 0.02 0.25 .05 
5 0.01 0.08                           -0.13 0.14 .85 
6                                              -0.03 0.06                           -0.13 0.08 .66   
7 0.04 0.06                           -0.09 0.13 .45 
8 Referent 0.00 0.00 0.00 0.00 Referent 
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Table 4. Adjusted Means of Symptom Severity according to Adherence, time and Patient Sex. 
Variable Mean Standard Error  
Adherence 
Non-adherence 16.99 0.08    
Adherent 15.17 0.60    
Sex 
Male 18.68 0.09    
Female 13.80 0.09    
 
AVR Call 
1 22.45 0.07    
2 18.90 0.08    
3 16.74 0.08    
4 16.05 0.08    
5 14.12 0.08    
6 13.73 0.09    
7 14.92 0.09    
8 14.05 0.09    
 
Groups 
Group 1: AVR Only 15.45 0.12      
 
Group 2: AVR + Nurse 15.86 0.10      
for Both Symptoms 
and Adherence     
 
Group 3: AVR + Nurse 16.90 0.90    
for Adherence Only 
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